Mostrar el registro sencillo del ítem

dc.contributor.authorPineda-Tenor, Daniel 
dc.contributor.authorBerenguer, Juan
dc.contributor.authorGarcia-Broncano, Pilar 
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorFernandez-Rodriguez, Amanda 
dc.contributor.authorDiez, Cristina
dc.contributor.authorGarcia-Alvarez, Monica 
dc.contributor.authorCarrero, Ana
dc.contributor.authorCatalán, Pilar
dc.contributor.authorAldámiz-Echevarria, Teresa
dc.contributor.authorResino, Salvador 
dc.date.accessioned2024-02-04T20:28:21Z
dc.date.available2024-02-04T20:28:21Z
dc.date.issued2014-05
dc.identifier.citationEur J Clin Invest. 2014 May;44(5):453-62.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17451
dc.description.abstractBackground: The adiponectin (ADIPOQ) rs2241766 polymorphism is related to metabolic abnormalities. The aim of this study was to evaluate the association of the ADIPOQ rs2241766 polymorphism with serum dyslipidemia and insulin resistance (IR) in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients. Methods: We carried out a cross-sectional study on 262 patients. ADIPOQ rs2241766 polymorphisms were genotyped by GoldenGate® assay. Generalized linear models (GLMs) were used to compare continuous outcome variables (total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C and homeostatic model assessment (HOMA)) and categorical outcome variables (TC≥200 mg/dL, TG≥170 mg/dL, LDL-C≥100 mg/dL, HDL-C≤35 mg/dL, non-HDL-C≥120 mg/dL and HOMA≥3·8) according to ADIPOQ genotype under a dominant inheritance model. Results: Patients with the rs2241766 GG/GT genotype had significantly lower serum TC levels (P=0·038) and percentages of TC≥200 mg/dL (P=0·022) than rs2241766 TT carriers. When adjusted GLM was performed, rs2241766 GG/GT was associated with low serum TC levels (arithmetic mean ratio (AMR)=0·92 [(95% CI=0·85; 0·99) P=0·024]) and low likelihood of TC≥200 mg/dL (odds ratio (OR)=0·32 [(95% CI=0·11; 0·88) P=0·027]. When stratifying by steatosis, no significant values were found for patients without steatosis. However, for patients with steatosis, rs2241766 GG/GT genotypes were related to low TC serum values of TC (AMR=0·89; P=0·027), LDL-C (AMR=0·85; P=0·039) and non-HDL-C (AMR=0·86; P=0·015). No significant associations were found between rs2241766 and HOMA values. Conclusions: The presence of the ADIPOQ rs2241766 G allele (GG/GT genotype) was associated with a protective effect against dyslipidemia, primarily in HIV/HCV-coinfected patients with steatosis.es_ES
dc.description.sponsorshipThis work has been supported by grants given by Fondo de Investigación de Sanidad en España (FIS) [Spanish Health Founds for Research] [grant numbers PI08/0738, PI11/00245, PI08/0928 and PI11/01556], Red Española de Investigación en SIDA (RIS) [AIDS Research Network] [grant numbers RD12/0017/0024 and RD12/0017/0004] and ‘Fundación para la Investigación y la Prevención del Sida en España’ (FIPSE) [grant number 361020/10]. DPT, PGB, MAJS, AFR, and MGA are supported by ‘Instituto de Salud Carlos III’ [grant numbers CM12/00043, FI12/00036, CM10/00105, PI11/00245, CD12/00442, respectively]. JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS)es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.type.hasVersionAMes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAdiponectines_ES
dc.subjectAIDSes_ES
dc.subjectChronic hepatitis Ces_ES
dc.subjectDyslipidemiaes_ES
dc.subjectMetabolic disturbancees_ES
dc.subjectSNPses_ES
dc.subject.meshAdiponectin es_ES
dc.subject.meshAdult es_ES
dc.subject.meshCholesterol, HDL es_ES
dc.subject.meshCholesterol, LDL es_ES
dc.subject.meshCoinfection es_ES
dc.subject.meshCross-Sectional Studies es_ES
dc.subject.meshDyslipidemias es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHIV Infections es_ES
dc.subject.meshHepatitis C, Chronic es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInsulin Resistance es_ES
dc.subject.meshMale es_ES
dc.subject.meshPolymorphism, Genetices_ES
dc.subject.meshTriglycerides es_ES
dc.titleAssociation of adiponectin (ADIPOQ) rs2241766 polymorphism and dyslipidemia in HIV/HCV-coinfected patientses_ES
dc.typeresearch articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID24528335es_ES
dc.format.volume44es_ES
dc.format.number5es_ES
dc.format.page453-562es_ES
dc.identifier.doi10.1111/eci.12250es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderRETICS-Sida (RIS-ISCIII) (España) es_ES
dc.contributor.funderFundación para la Investigación y la Prevención del Sida en España es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1365-2362es_ES
dc.relation.publisherversionhttps://doi.org/10.1111/eci.12250es_ES
dc.identifier.journalEuropean journal of clinical investigationes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//CD12%2F00442/ES/CD12%2F00442/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//PI11%2F00245/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//CM10%2F00105/ES/CM10%2F00105/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//FI12%2F00036/ES/FI12%2F00036/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//CM12%2F00043/ES/CM12%2F00043/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0004/ES/SIDA/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MINECO//RD12%2F0017%2F0024/ES/SIDA/ es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/MICINN//PI11%2F01556/ES/Erradicación del VHC en pacientes coinfectados por VIH%2FVHC: efectos sobre la inflamación, el daño endotelial, la activación inmune y la aterosclerosis preclínica/ es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI08/0928es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/PI08/0738es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional